Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Fecal transplant: “where, when, how much” needed to optimize effects on IBS?
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Fecal transplant: “where, when, how much” needed to optimize effects on IBS?
Gastroenterology

Fecal transplant: “where, when, how much” needed to optimize effects on IBS?

IBS
Gastroenterology

What is the best combination of factors for fecal transplantation as a treatment for irritable bowel syndrome (IBS)? According to Norwegian researchers and clinicians, a transplant dose of between 60 g and 90 g into the small intestine, rather than the colon, and ideally repeated.

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 20 October 2023
Updated 09 September 2024

44% Only 2 out of 5 people said their doctor had informed them of the appropriate behaviors to adopt to preserve their microbiota balance

Learn more:
The International Microbiota Observatory

Between 2015 and 2020, fecal microbiota transplant (FMT) as a treatment for irritable bowel syndrome (IBS) was tested in seven randomized controlled trials (RCTs). The outcomes of these RCTs varied considerably, probably due to differences in the protocols used. A Norwegian team studied the effects of FMT dose, repetition, and area of administration, using the same protocol as in their previous RCT, which saw very good results (long-standing effects up to three years after FMT, with only a few mild adverse effects). The transplant came from the same (sidenote: Super-donor A donor with high microbial diversity, whose microbiota quality conditions FMT results. In this case, a healthy, non-smoking 40-year-old Caucasian male born vaginally, breastfed, who had taken only a few courses of antibiotics during his life, took no medication regularly, had a normal BMI, exercised regularly, and took sport-specific dietary supplements (which made his diet richer than average in protein, fiber, minerals, and vitamins). ) .

22.11.2021 Irritable bowel syndrome: is fecal microbiota transplantation effective in the long term? Read more

Symptoms improved with repeated FMT

This new study included 186 patients suffering from irritable bowel syndrome, randomized into three groups receiving a 90 g fecal transplant (versus 30 g or 60 g in the previous RCT) either to the colon, to the duodenum, or twice to the duodenum with a one-week interval.

In the year following the FMT, the researchers observed a much lower prevalence of (sidenote: Assessed using the IBS-SSS, the Birmingham IBS Symptom Questionnaire (BSQ) and the Fatigue Assessment Scale (FAS). ) , regardless of the group and the time elapsed since FMT: present in 75% of patients on the day of transplantation, they affected 17%-32% (depending on the group) after 3 months, and 24%-41% after one year. Similarly, (sidenote: Assessed using the IBS Quality of Life Instrument (IBS-QoL) and Short-Form Nepean Dyspepsia Index (SF-NDI) questionnaire. ) improved in all three groups, regardless of the time elapsed since FMT. Moreover, repeating transplantation improved the beneficial effects on symptoms and quality of life.

Your IBS Diagnosis Check List

Learn more

Favoring the small intestine over the colon

An analysis of fecal samples (16s rRNA) taken at baseline and at 3, 6, and 12 months after FMT showed a significant reduction in dysbiosis in all treatment groups. Bacterial profiles changed considerably following FMT for all three groups and at all observation dates, with differences between the groups. These changes notably concerned six bacteria linked to symptoms and fatigue, such as Alistipes spp., implicated in several diseases such as depression, anxiety, and chronic fatigue syndrome, or Holdemanella biformis, which has anti-inflammatory effects.

29.11.2022 Everything you need to know about Irritable Bowel Syndrome (IBS) Read more

Transplanting into the small intestine enables the colonization of beneficial bacteria over the long term, unlike transplanting into the colon, where the effect appears to be more transient. Conversely, while the beneficial effect increased with dose in the previous RCT (greater effect at 60 g than at 30 g), the 90 g dose has no additional benefit compared with the 60 g already tested: the optimal dose would therefore be between 60 g and 90 g.

Explain fecal transplantation to your patients with this dedicated content: 

10.12.2020 Fecal transplant Read more
Sources

El-Salhy M, Gilja OH, Hatlebakk JG. Factors affecting the outcome of fecal microbiota transplantation for patients with irritable bowel syndrome. Neurogastroenterol Motil. 2023 Jul 10:e14641.

Tags
Dysbiosis Depression Microbiome Flora

    See also

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis
    The role of Bifidobacteria in irritable bowel syndrome (IBS)
    Created 20 October 2023
    Updated 09 September 2024

    About this article

    To know more about this topic.

    Main topic

    IBS

    Medical practice

    Gastroenterology

    Content type

    News
    Gastroenterology

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irrita...

    Find out more

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 year...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to sug...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgi...

    Find out more

    Focus on antibiotic associated diarrhea (AAD)

    Find out more

    Dampening gastrointestinal inflammation through nutrition

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo